Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage

Bioinformatics

Volumn 29, Issue 4, 2013, Pages 451-460

  Chen, Mengjie ^a   Svicher, Valentina ^b   Artese, Anna ^c   Costa, Giosué ^c   Alteri, Claudia ^b   Ortuso, Francesco ^c   Parrotta, Lucia ^c   Liu, Yang ^a   Liu, Chang ^a   Perno, Carlo Federico ^b   Alcaro, Stefano ^c   Zhang, Jing ^a  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c Magna Græia University   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CHEMISTRY; CLASSIFICATION; GENETICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MOLECULAR DOCKING; MUTATION; STATISTICAL MODEL; VIROLOGY;

GENOTYPE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MODELS, STATISTICAL; MOLECULAR DOCKING SIMULATION; MUTATION; RECEPTORS, CCR5; RECEPTORS, CXCR4;

MLCS; MLOWN;

EID: 84874337197     PISSN: 13674803     EISSN: 14602059     Source Type: Journal    
DOI: 10.1093/bioinformatics/btt002     Document Type: Article

References (38)

1. Alcaro, S. et al. (2010a) Computational analysis of Human Immunodeficiency Virus (HIV) Type-1 reverse transcriptase crystallographic models based on significant conserved residues found in Highly Active Antiretroviral Therapy (HAART)-treated patients. Curr. Med. Chem., 17, 290-308.
2. Alcaro, S. et al. (2010b) Rational design, synthesis, biophysical and antiproliferative evaluation of fluorenone derivatives with DNA G-quadruplex binding properties. Chem Med Chem, 5, 575-583.
3. Berger, E.A. et al. (1998) A new classification for HIV-1. Nature, 391, 240.
4. Bowers, K.J. et al. (2006) SC '06 Proceedings of the 2006 ACM/IEEE Conference on Supercomputing. New York, NY.
5. Cardozo, T. et al. (2007) Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res. Hum. Retroviruses, 23, 415-426.
6. Church, J.D. et al. (2008) HIV-1 tropism and survival in vertically infected Ugandan infants. J. Infect. Dis., 197, 1382-1388.
7. Dorr, P. et al. (2005) Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother., 49, 4721-4732.
8. Dumonceaux, J. et al. (2001) Determination of essential amino acids involved in the CD4-independent tropism of the X4 human immunodeficiency virus type 1 m7NDK isolate: role of potential N glycosylations in the C2 and V3 regions of gp120. J. Virol., 75, 5425-5428.
9. Gasteiger, J. and Marsili, M. (1980) Iterative partial equalization of orbital electronegativity-a rapid access to atomic charges. Tetrahedron, 36, 3219-3228.
10. Goodford, P.J. (1985) A computational procedure for determining energetically favourable binding sites on biologically important macromolecules. J. Med. Chem., 28, 849-857.
11. Hoffman, T.L. and Doms, R.W. (1999) HIV-1 envelope determinants for cell tropism and chemokine receptor use. Mol. Membr. Biol., 16, 57-65.
12. Huang, C.C. et al. (2005) Structure of a V3-containing HIV-1 gp120 core. Science, 310, 1025-1028.
13. Huang, C.C. et al. (2007a) Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science, 28, 1930-1934.
14. Huang, W. et al. (2007b) Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous compositionof viral populations. J. Virol., 81, 7885-7893.
15. Jorgensen, W.L. et al. (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc., 118, 11225-11236.
16. Kaminski, G.A. et al. (2001) Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J. Phys. Chem. B, 105, 6474-6487.
17. Kuiken, C. et al. (eds) (2010) HIV Sequence Compendium 2010. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, NM. LA-UR 10-03684.
18. Lihana, R.W. et al. (2009) HIV-1 subtype and viral tropism determination for evaluating antiretroviral therapy options: an analysis of archived Kenyan blood samples. BMC Infect. Dis., 9, 215-223.
19. McDonald, D.Q. and Still, W.C. (1992) AMBER torsional parameters for the peptide backbone. Tetrahedron Lett., 33, 7743-7746.
20. Mohamadi, F. et al. (1990) MacroModel-an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem., 11, 440-467.
21. Moreno, S. et al. (2009) Prevalence of CCR5-tropic HIV-1 among treatmentexperienced individuals in Spain. HIV Clin. Trials, 10, 394-402.
22. Ortuso, F. et al. (2006) GBPM: GRID-based pharmacophore model: concept and application studies to protein-protein recognition. Bioinformatics, 22, 1449-1455.
23. Parczewski, M. et al. (2010) Analysis of V3 loop sequences using various bioinformatic tools designed for genotypic HIV-1 tropism testing. HIV AIDS Rev., 9, 65-67.
24. Princen, K. and Schols, D. (2005) HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokine Growth Factor Rev., 16, 659-677.
25. Regoes, R.R. and Bonhoeffer, S. (2005) The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol., 13, 269-277.
26. Sander, O. et al. (2007) Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. PLoS Comput. Biol., 3, e58.
27. Shepherd, J.C. et al. (2008) Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J. Infect. Dis., 198, 1104-1112.
28. Still, W.C. et al. (1990) Semianalytical treatment of solvation for molecular mechanism and dynamics. J. Am. Chem. Soc., 112, 6127-6129.
29. Svicher, V. et al. (2011a) Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage. Antivir. Ther., 16, 1035-1045.
30. Svicher, V. et al. (2011b) HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. Antiviral Res., 90, 42-53.
31. Svicher, V. et al. (2011c) Key-genetic elements in HIV-1 gp120 V1, V2, and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N-terminus and HIV-1 antigenic potential. Antivir. Ther., 16, A14-A14.
32. Svicher, V. et al. (2011d) Specific HBsAg genetic-determinants are associated with occult HBV-infection in vivo and HBsAg-detection. Antivir. Ther., 16, A85-A85.
33. Svicher, V. et al. (2012) Novel HBSag markers tightly correlate with occult HBV infection and strongly affect HBSag detection. Antiviral Res., 93, 86-93.
34. Trott, O. and Olson, A.J. (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem., 31, 455-461.
35. Veldkamp, C.T. et al. (2008) Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci. Signal., 1, ra4.
36. von Itzstein, M. et al. (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature, 363, 418-423.
37. Zhang, J. et al. (2010) Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance. PNAS, 107, 1321.
38. Zhang, J. et al. (2012) Systematic investigation on interactions for HIV drug resistance and cross-resistance among protease inhibitors. Proteome Sci. Comput. Biol., 1, 2.